Search
PD-168393
go.drugbank.com/drugs/DB07662ExperimentalPD-168393 is an epidermal growth factor receptor inhibitor.
GSK-923295
go.drugbank.com/drugs/DB06097InvestigationalGSK-923295 demonstrated a broad spectrum of activity against a range of human tumor xenografts grown in nude mice, including models of colon, breast, ovarian, lung and other tumors. … GSK-923295 is a small-molecule inhibitor of the mitotic kinesin centromere-associated protein E (CENP-E), and the third novel drug candidate to arise from Cytokinetics' broad strategic alliance with GlaxoSmithKline
Lemzoparlimab
go.drugbank.com/drugs/DB17572InvestigationalLemzoparlimab is under investigation in clinical trial NCT04912063 (Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Partic...
Romlusevimab
go.drugbank.com/drugs/DB16494InvestigationalRomlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.
BL-1020
go.drugbank.com/drugs/DB05687InvestigationalBL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Tozorakimab
go.drugbank.com/drugs/DB16473Investigationalhistory of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a
VGA039
go.drugbank.com/drugs/DB18385InvestigationalVGA039 is an IgG4 monoclonal antibody directed against protein S.
LGD2941
go.drugbank.com/drugs/DB05234ExperimentalLGD2941 is a non-steroidal, selective androgen receptor modulator (SARM) developed jointly by Ligand and TAP.
Alunacedase alfa
go.drugbank.com/drugs/DB15736InvestigationalAlunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Cathine
go.drugbank.com/drugs/DB01486ExperimentalIllicitIn the United States, it is classified as a Schedule IV controlled substance. … Cathine, also known as d-norpseudoephedrine and (+)-norpseudoephedrine, is a psychoactive drug with stimulant properties. It belongs to the phenethylamine and amphetamine chemical classes.